ABSTRACT
In recent years, biochemical and biophysical studies carried out with purified receptors (1) in heterologous expression systems (2, 3) or native tissue (4 -6) unequivocally demonstrate that many G-protein-coupled receptors (GPCRs) can form homo-and heterooligomers. It was proposed that oligomerization occurs early in the biosynthetic pathway, most likely in the endoplasmic reticulum (ER) where it could play a role in the quality control (7) as well as in anterograde and retrograde trafficking of the receptors to and from the plasma membrane (8) . Heterooligomerization has also been proposed to contribute to the pharmacological and signaling diversity. Indeed, it has been shown for many pairs of receptors that the formation of such heterocomplexes can result in binding and/or signaling profiles that differ from those of the homooligomer pathways (9, 10) . Although strict dimers have been demonstrated only in the case of the metabotropic glutamate receptors (mGluRs; refs. 11, 12) , the law of parsimony has led most investigators to assume that the oligomers represent receptor dimers. In some cases, however, the existence of GPCR tetramers and even higher order oligomers has been suggested (11, (13) (14) (15) (16) (17) (18) , but the capacity of receptor dimers or larger oligomers to directly engage signaling effectors remains to be established.
C-X-C chemokine receptor type 4 (CXCR4) and chemokine receptor 2 (CCR2) are among the GPCR family A members for which the strongest evidence for homo-and heterooligomerization has been gathered in both reconstituted and native systems, with data supporting a role in the physiological responses (19 -22) . Both receptors trigger cell chemotaxis on binding of their specific peptide ligands [stromal cell-derived factor 1 (SDF-1)/CXCL12 for CXCR4 and monocyte chemotactic protein 1 (MCP-1)/CCL2 for CCR2] and play central roles in immune and inflammatory responses (23) as well as cancer metastasis (24, 25) . In addition to these roles, CXCR4 is also known as an important mediator of hematopoietic stem cell homing to the bone marrow (26) and is known to act as a coreceptor for HIV entry (27) . Both receptors couple to G␣ i , the inhibition of cAMP production being one of their main signaling pathways but have also been shown to activate the p38 MAPK (28) and ERK1/2, partly in a ␤arrestin-dependent manner (29 -31) .
The existence of CCR2 and CXCR4 homo-and heterooligomers was first suggested by coimmunoprecipitation, as well as fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) studies performed in heterologous systems, revealing the presence of Ն2 receptor molecules in proximity (20 -22, 32-34) . The presence of both homo-and heterooligomers at the cell surface was supported by the observation that binding of cell impermeant ligands promoted changes in the BRET signal observed between 2 receptor molecules (19, 20, 32) . The observation of negative binding cooperativity between CXCR4 and CCR2 ligands and signaling crosstalk in human CD4 ϩ T lymphocytes, which endogenously coexpressed both receptors, was taken as further evidence for dimerization and its physiological relevance (19) . Both receptors are also found coexpressed in monocytes and dendritic cells (35) where a potential role for the CCR2-CXCR4 heterodimer has been proposed based on the observation that an anti-CCR2 antibody prevents CXCR4-mediated HIV replication (34) . Structural evidence for the existence of CXCR4 dimers was recently provided by the resolution of the 3D crystal structure of CXCR4 that revealed a consistent homodimer interface of 850 Å 2 of buried surface that involves interactions between transmembrane domains 5 and 6 (36) .
Despite the widely used term dimer when referring to GPCR oligomers, an increasing number of studies suggest that some GPCRs can form higher-order oligomers. For instance, quantitative radioligand binding assays coupled to cross-linking experiments suggested that the M2 muscarinic receptor can form tetramers (37) . Using a sequential 3-FRET approach, LopesGimenes et al. (38) suggested that the ␣1b-adrenergic receptor formed at least trimers. CXCR4, CCR5, and CCR2 have been shown to form heterocomplexes composed of Ն3 partners (21) , and complemented donoracceptor resonance energy transfer assays performed on the D2-dopamine receptor (16) as well as SNAP-TAG-based time-resolved FRET on the GABAb receptor (11, 17, 39 -41) revealed the existence of tetramers. Whether such higher-order oligomers can directly engage downstream signaling effectors has not been investigated. The present study therefore aims at assessing whether CXCR4 and CCR2 can assemble into functional complexes larger than dimers that can engage their signaling partners. For this purpose, bimolecular fluorescence complementation (BiFC) and bimolecular luminescence complementation (BiLC) assays were combined with BRET analysis to verify the possible formation of CXCR4 and CCR2 homo-and heterotetramers and the ability of these oligomers to interact with G proteins and ␤arrestin. Our study shows that homodimers of CXCR4 can assemble with either a CCR2 homodimer or another CXCR4 homodimer to form tetramers. In addition, we found that selective agonist binding promotes a conformational rearrangement of the CCR2/CXCR4 heterooligomer that leads to the engagement of G␣ i1 and ␤arrestin by the heterooligomer, as well as synergistic calcium mobilization that suggests transprotomer regulation. In contrast to CXCR4, CCR2 was found to efficiently activate G␣ z ; a coupling that most likely underlies the pertussis toxin (PTX)-resistant calcium response component observed for CCR2. Equivalent G␣ z activation and PTX-resistant calcium responses were observed on costimulation of the two receptors, suggesting that the CXCR4/CCR2 heterooligomer can also stimulate the G␣ z -promoted calcium mobilization. This demonstration of the existence of a functional heterotetramer provides new mechanistic insights to explain the crosstalk regulation occurring between these two important chemokine receptors.
MATERIALS AND METHODS

Plasmids
All fusion proteins in this study were subcloned in the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). CXCR4-L1 was PCR amplified and inserted into NotI-ClaI sites of the PKA-F(1) described previously (42) . RlucII was derived from Renilla luciferase, where 2 mutations (C124A and M185V) were introduced by side-directed mutagenesis to make it brighter. The last 606 nucleic acids of RlucII construct were PCR amplified and inserted into ClaI-XbaI sites ofsity, New York, NY, USA) and have been described previously (16) . To generate CXCR4-V1, CCR2-V1, CXCR4-V2, and CCR2-V2, cDNA of CXCR4 and CCR2 was PCR amplified and subcloned into the HindIII restriction sites of D2Rs-V1 and D2Rs-V2, respectively. To generate the Myc-tagged receptors, CCR2 and D2Rs were PCR amplified with a 5= oligonucleotide containing the Myc tag sequence and subcloned into the HindIII-XbaI restriction sites of the pcDNA3.1 vector. To generate CCR2-vYFP and D2R-vYFP, the venus yellow fluorescent protein (vYFP) encoding sequence was PCR amplified and inserted into XhoI-XbaI restriction sites from CCR2-V1 and D2R-V1 described above. G␣ i1 -RlucII was created using the same strategy as described previously (43) to generate G␣ i2 -and G␣ i3 -RlucII. GFP10-G␥ 1 and G␣z-94Rluc were created using the same strategy as described previously (44) to generate GFP10-G␥ 2 and G␣ i1 -91Rluc, respectively. The plasmid encoding the G␤ 1 subunit was bought from Missouri University of Science and Technology (Rolla, MO, USA; http://cdna.org). The following plasmids were previously described: G␣ i1 -91Rluc (44), RlucII-G␣ 13 (24) , CXCR4-Rluc and CXCR4-YFP (20) , CXCR4-N119K-vYFP (32), h␤arrestin2-RlucII (45) , and obelin (46) .
Cell culture and transfection
HEK293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum, 100 U/ml penicillin/streptomycin, and 2 mM l-glutamine (Wisent, St-Bruno, QC, Canada) and incubated at 37°C in 5% CO 2 . At 24 h before transfection, cells were seeded at a density of 5 ϫ 10 5 cells/well in 6-well dishes. At 48 h before the experiments, cells were transfected using polyethylenimine (PEI; 25 kDa linear; Polysciences, Warrington, PA, USA) at 3:1 PEI/DNA ratio. Each of the expression vectors was diluted in 150 mM NaCl, and the total quantity of DNA was completed to 3 g with salmon sperm DNA (Invitrogen). After overnight incubation, transfection medium was replaced with fresh DMEM for 4 h to allow cell recovery. Transfected cells were then detached and seeded in 96-well white plates (Culturplate; PerkinElmer, Waltham, MA, USA) pretreated with polyornithine (Sigma-Aldrich, St. Louis, MO, USA) and left in culture for an additional 24 h before being processed for BRET assay. For monitoring the engagement of G proteins, cells were detached on the day of the experiment and distributed in 96-well microplates (Optiplate; PerkinElmer).
BRET measurements
The expression levels of the energy acceptor (vYFP or splitvYFP)-tagged proteins were measured as total fluorescence using a FlexStationII microplate reader (Molecular Devices, Sunnyvale, CA, USA) with excitation at 480 nm and emission at 530 nm. BRET readings were collected using a Mithras LB940 microplate reader (Berthold Technologies, Bad Wildbad, Germany) 10 min after addition of the luciferase substrate, coelenterazine h (5 M; NanoLight Technology, Pinetop, AZ, USA), with a sequential integration of the donor emission at 485 Ϯ 20 nm and acceptor emission at 530 Ϯ 20 nm. BRET signals were derived from the emission detected with the energy acceptor filter divided by the emission detected using the energy donor filter. The net BRET signals were obtained by subtracting the BRET signal obtained in cells expressing the Rluc-fused constructs alone. BRET values were monitored in the presence and absence of CXCR4, CCR2, and dopamine agonists for the indicated times. For all experiments, coelentrazine h (2.5 M) was added to the cells, and BRET measurement was collected. For time-course experiments, readings were collected for the indicated times following the addition of the drugs. To avoid the possibility that any difference between BRET signals may be due to different expression levels, BRET comparisons between conditions were all performed at similar acceptor-donor ratios, as measured by the total luminescence and fluorescence signals. All experiments were carried out at acceptor/donor ratios yielding maximal or near-maximal BRET responses.
BRET-protein complementation assay (PCA) measurements
The complementary fragments of RlucII and vYFP were subcloned, in frame, at the C terminus of the receptors. The L1 fragment was composed of the residues 1-330 from RlucII, whereas the L2 fragment comprised residues 331-936 of RlucII. The V1 fragment was composed of residues 1-465 from vYFP, whereas the V2 fragment encompassed residues 466 -720 of vYFP. For BiFC and BiLC experiments, cells were transfected with only one (CXCR4-L1, CXCR4-L2, CXCR4-V1, CXCR4-V2, CCR2-V1, CCR2-V2, D2R-V1, or D2R-V2) or both complementation pairs (CXCR4-L1/CXCR4-L2, CXCR4-V1/CXCR4-V2, CCR2-V1/CCR2-V2, or D2R-V1/D2R-V2). Total luminescence or fluorescence of the individual construct or the complementation pair was measured to assess the background level and extent of complementation, respectively. BRET assays were then performed as described above for the nonsplit donor and acceptor (-RlucII and -vYFP).
G-protein activation and calcium mobilization assays
HEK293T cells were transfected in suspension (3.5ϫ10 5 cells in 1 ml) with 1 g total DNA using 25 kDa linear PEI at 3:1 PEI/DNA ratio and seeded in 96-well white Culturplates (ϳ3ϫ10 4 cells/well) pretreated with poly-d-lysine (Fisher, Ottawa, ON, Canada) for calcium or polyornithine for G␣ i1 and G␣ z protein activation experiments.
G-protein activity was monitored using a BRET-based biosensor composed of G␣ i1 -RlucII or G␣ z -94RlucII and GFP10-G␥ 1 , in the presence of the untagged G␤ 1 subunit and CXCR4, CCR2, or D2 receptors, as indicated. The expression level of the energy acceptor (GFP10-G␥ 1 )-tagged protein was measured as total fluorescence using a FlexStationII microplate reader with excitation at 400 nm and emission at 510 nm. At 48 h after transfection, cells were washed once with PBS and incubated in Tyrode-HEPES buffer (137 mM NaCl, 0.9 mM KCl, 1 mM MgCl 2, 11.9 mM NaHCO 3 , 5.5 mM glucose, 3.6 mM NaH 2 PO 4, 25 mM HEPES, and 1 mM CaCl 2 , pH 7.4) supplemented with 0.1% BSA. Cells were then treated with or without ligands for the indicated times, and BRET values were monitored using a TriStar 2 LB 942 Multidetection Microplate Reader (Berthold Technologies), equipped with BRET400-GFP2/10 filter set (acceptor, 515Ϯ20 nm; and donor, 400Ϯ70 nm filters), 5 min after the addition of 2.5 M of coelenterazine 400-a (Biotium, Hayward, CA, USA). BRET signals were analyzed as described above.
Obelin biosensor was used as a calcium reporter as described previously (46) . At 48 h after transfection, cells were washed once with Tyrode-HEPES buffer and preincubated with the obelin substrate, coelenterazine cp (1 M; Biotium) for 2 h in the dark. MCP-1 and/or SDF-1, diluted in Tyrode/ 0.1% BSA, was injected at 100 nM final concentration, and luminescence was measured using SpectraMax L (Molecular Devices). PTX (100 ng/ml) treatment was done overnight at 37°C.
Flow cytometry
To evaluate CXCR4 relative expression levels in the BRET and BRET-PCA experiment configurations, transfected HEK293 cells or cord blood mononuclear cells were directly stained in PBS containing Fc block solution 24G2 (anti-CD16/32-FcR␥) using an anti-human CXCR4 antibody [PerCP/Cy5.5 anti-human CD184 (CXCR4) antibody; BioLegend, San Diego, CA, USA] for 45 min on ice. Cells were washed, resuspended in PBS and analyzed through a LSR II flow-cytometer (BD Biosciences, Mississauga, ON, Canada) set to detect PerCP/Cy5.5. Fluorescence compensations were applied to prevent the fluorescence interference coming from the vYFP-or the reconstituted vYFP-tagged receptors (CXCR4-vYFP, CXCR4-V1/CXCR4-V2, or CXCR4-V1/CCR2-V2). Data analysis was performed using BD FACSDiva (BD Biosciences) and FlowJo (TreeStar Inc., Ashland, OR. USA) software.
Cell surface ELISA
Cells were transfected in parallel with the transfection done for the BRET experiments. The day of the experiment, cells destined for ELISA determination were fixed for 5 min with 3% paraformaldehyde directly in 96-well microplates (Culturplate; PerkinElmer). Mouse anti-Myc 9E10 primary antibody was used to assess cell surface expression levels of myc-tagged CCR2 or D2R constructs. The primary antibody was incubated for 30 min at room temperature, followed by extensive washing of the cells and addition of the secondary horseradish peroxidase(HRP)-conjugated sheep IgG anti-mouse Ab (GE Healthcare, Pittsburgh, PA, USA) for 30 min at room temperature. Following extensive washing, total luminescence was measured 6 min after the addition of the HRP substrate superSignal West Femto (Thermo Scientific, Burlington, ON, Canada) using a Mithras LB940 microplate reader.
Statistical analysis
Statistical significance of the difference between 2 conditions was assessed using unpaired 2-tailed Student's t test. Differences between multiple conditions (Ͼ3) were determined by 1-way ANOVA followed by Bonferroni's multiple comparison test. Values of P Ͻ 0.05 were considered significant. All tests werre carried out with Prism 4.0 software (GraphPad, La Jolla, CA, USA).
RESULTS
Effect of CCR2 activation on CXCR4 homodimer
To test the possible functional interaction between a dimer of human CXCR4 and CCR2, we first assessed the effect of activating CCR2 on the BRET signal between 2 CXCR4 receptors fused to Rluc and vYFP. As for the following experiments, these studies were performed in HEK293 cells transiently expressing the constructs at levels similar to those observed in mononucleated cells from human cord blood that endogenously express CXCR4 and CCR2 receptors (Supplemental Fig. S1 ). As shown in Fig. 1A , and as previously reported (20) , direct stimulation of cells coexpressing CXCR4-Rluc and CXCR4-vYFP with the selective CXCR4 agonist SDF-1 led to a significant increase in BRET, with an EC 50 (4.6 nM) compatible with the affinity of human SDF-1 for CXCR4. In cells expressing CCR2 in addition to CXCR4-Rluc and CXCR4-vYFP ( Fig. 1B) , stimulation with the CCR2-specific agonist human MCP-1 also resulted in a concentrationdependent increase in BRET between the 2 CXCR4 protomers, with an EC 50 (19.9 nM), consistent with the K d of MCP-1 for CCR2 (47, 48) . As previously reported (20) , the selective CXCR4 inverse agonist TC14012 decreased the basal BRET between CXCR4-Rluc and CXCR4-vYFP, reflecting its action on the homooligomer (Fig. 1C) . However, TC14012 did not block the transreceptor modulation of the BRET signal promoted by MCP-1, confirming that it resulted from CCR2 and not CXCR4 activation. No effect on the CXCR4-Rluc/CXCR4-vYFP BRET signal was observed on coexpression and stimulation of another G␣ icoupled receptor, the D2R (Fig. 1D ), expressed at similar cell surface expression level (Supplemental Fig.  S2A ), demonstrating the selectivity of the phenomenon. The effect of MCP-1 required CCR2, since no significant BRET change was observed following MCP-1 stimulation in cells expressing only CXCR4-Rluc and CXCR4-vYFP (Fig. 1D ). These results indicate that CCR2 activation affects the CXCR4 oligomer, either by modulating the conformation of the dimer or promoting dimerization.
Although we cannot rule out that the effect of CCR2 on the CXCR4 dimer could result from CCR2 downstream signaling, the data are consistent with the possible formation of a complex between CCR2 and a dimer of CXCR4. To directly test this latter possibility, we combined protein complementation and BRET (16, 49, 50) . The PCA used is based on the ability of 2 fragments of Rluc to reconstitute a luminescent protein when brought into proximity (42) . The Rluc L1 and L2 fragments (Supplemental Fig. S3A ) were fused to 2 CXCR4 constructs, and the ability of their coexpression to generate a luminescent signal and to yield a BRET signal with a CCR2-vYFP was assessed. Coexpression of CXCR4-L1 and CXCR4-L2 led to a specific luminescent signal (Supplemental Fig. S3B ), confirming the formation of homodimers. In cells expressing CXCR4-L1, CXCR4-L2, and CCR2-vYFP, a basal BRET signal was detected, and stimulation of the cells with MCP-1 led to a significant increase of the signal ( Fig. 2A) , indicating that CCR2 activation promotes a rearrangement of a ternary complex composed minimally of a dimer of CXCR4 and a monomer of CCR2. Coexpression and stimulation of D2R-vYFP at similar expression levels, as monitored by fluorescence and luminescence, did not mimic the effect of CCR2-vYFP ( Fig. 2A) , ruling out nonselective interactions among GPCRs.
Higher-order oligomers of CXCR4-CCR2 complexes
The above results suggest the formation of an oligomeric complex between a dimer of CXCR4 and at least a monomer of CCR2 and would be consistent with the possibility that the complex may be formed by the association between homodimers of CXCR4 and CCR2. This possibility is further supported by the fact that, similarly to CXCR4, CCR2 has been shown to form homodimers (20, 51) . To test the possible formation of a heterotetramer composed of CXCR4 and CCR2 homodimers, we extended the PCA-BRET assays to include split Rluc and split vYFP (Supplemental Fig. S4A ) constructs that allow to monitor the interaction among 4 partners simultaneously (16, 52) . As predicted from the previously reported dimerization of CXCR4, CCR2, or D2R, coexpression of the identical protomer pairs fused to V1 and V2 vYFP fragments led to the reconstitution of vYFP, yielding a robust fluorescent signal (Supplemental Fig. S4B ). As shown in Fig. 2B , coexpressing CXCR4-L1, CXCR4-L2, CCR2-V1, and CCR2-V2 led to a significant BRET signal, which was increased on activation of CCR2 by MCP-1, consistent with the existence of a heterooligomeric complex composed of a minimum of 2 CXCR4 and 2 CCR2 molecules. Despite the fluorescence signal generated by the coexpression of D2R-V1 and D2R-V2 (Supplemental Fig. S4B ), which confirms the formation of D2R homooligomers (16), the dopamine agonist quinpirole failed to promote any modulation of the marginal BRET detected in cells coexpressing CXCR4L1/L2 with D2R-V1/V2 (Fig. 2B) , confirming the selectivity of the CXCR4-CCR2 interactions.
The observation of heterooligomers involving at least a tetramer composed of 2 CCR2 and 2 CXCR4 molecules raises the question of whether the previously described homodimers (20 -22, 32-34) could also be part of larger homooligomeric complexes. To test this hypothesis, we coexpressed CXCR4-L1 and CXCR4-L2 with CXCR4-V1 and CXCR4-V2. As shown in Fig. 2C , inset, a significant BRET signal was observed, indicating the formation of at least a homotetramer. The observed BRET signal increased in a dose-dependent manner on SDF-1 stimulation (Fig. 2C) , demonstrating that the homooligomer is present at the cell surface and is responsive to the peptide chemokine. Interestingly, the EC 50 of SDF-1 to promote the BRET signal changes in the homotetrameric (Fig. 2C) and homodimeric (Fig.  1A) configurations was very similar (3.9 vs. 4.6 nM).
Engagement of G proteins by a CXCR4/CCR2 heterooligomer
To determine whether the oligomers could engage their cognate G proteins, we first assessed the ability of a homodimer of CXCR4 to engage G␣ i1 and G␣ 13 , as both these G-protein subtypes have previously been shown to couple to CXCR4 (24, 45) . Stimulation with SDF-1 led to a concentration-dependent change in BRET between CXCR4-V1/V2 and G␣ i1 -91Rluc and Rluc-G␣ 13 (Fig. 3A, C) , and both responses were dosedependently inhibited by a pretreatment with TC14012 ( Fig. 3) , confirming the pharmacological selectivity of the signal. Interestingly, whereas the EC 50 of SDF-1 to promote the engagement of G␣ i1 by the homodimer was similar to that observed for the SDF-1-promoted conformational change of the dimer (2.2 vs. 4.6 nM), the EC 50 for G␣ 13 coupling was shifted to the right by 1 order of magnitude (45.6 nM), indicating a lower affinity of the SDF-1-bound homodimer for G␣ 13 vs. G␣ i1 . Consistent with this notion, TC14012 had a slightly greater potency to block the SDF-1 promoted engagement of G␣ 13 vs. G␣ i1 (18.5 vs. 59.1 nM). As can be seen in Fig. 3A , C, whereas SDF-1 promotes an increase in the BRET signal between CXCR4-V1/V2 and G␣ i1 -91Rluc, it induces a decrease in BRET between CXCR4-V1/V2 and Rluc-G␣ 13 . A similar inverse orientation of the BRET response has previously been observed between these two G-protein biosensors on engagement by a monomeric CXCR4-GFP2 (24, 45) . Such differences in the BRET signals reflect the different position of the energy donor and acceptors in the signaling complex. This influence of the position of the BRET pairs in the complex is well illustrated in Supplemental Fig. S5 . Indeed, whereas SDF-1 promotes an increase in BRET between CXCR4-V1/V2 and G␣ i1 -91Rluc or G␣ i1 -60Rluc, the chemokine leads to a decrease in BRET between CXCR4-V1/V2 and G␣ i1 -122Rluc. Similar results had been observed for the ␣2-adrenergic receptor (44) . Following this demonstration that oligomeric CXCR4 engages G␣ i1 and G␣ 13 on SDF-1 stimulation, we assessed whether a heterooligomer composed of a CXCR4 homodimer and a minimum of 1 CCR2 molecule could also engage G proteins by monitoring the effect of MCP-1 stimulation on the BRET between CXCR4-V1/V2 and G␣ i1 -91Rluc in cells coexpressing CCR2. As shown in Fig. 4A , the selective activation of CCR2 by MCP-1 promoted a significant BRET increase between the CXCR4 dimer and G␣ i1 . No such increase was observed in cells not cotransfected with CCR2, demonstrating that the G protein was engaged by the heteromeric complex. The selectivity of the effect was further supported by the fact that the dopamine agonist quinpirole did not promote any BRET change between the CXCR4 dimer and G␣ i1 in cells coexpressing D2R to the same level as CCR2 ( Fig. 4A and Supplemental Fig. S2B ). No engagement of G␣ 13 could be observed in this heterooligomeric configuration (data not shown), suggesting either that the heterodimer in unable to engage G␣ 13 or that the signal is too weak to be detected.
To weigh the implication of CXCR4 in the MCP-1-promoted increase in BRET between the CXCR4 and G␣ i1 and rule out a simple recruitment of G␣ i to CCR2, we took advantage of a mutant form of CXCR4 unable to activate G␣ i . CXCR4-N119K is compromised in its ability to promote GTP␥S binding to G␣ i1 despite a normal cell surface expression (32) . The altered coupling of CXCR4-N119K to G␣ i1 was confirmed by the inability of SDF-1 to promote a BRET increase between the receptor and G␣ i1 , in contrast with the robust SDF-1-promoted BRET observed between wild-type (WT)-CXCR4 and G␣ i1 (Fig. 4B) . The MCP-1-promoted BRET between CXCR4 and G␣ i1 in cells coexpressing CCR2 was greatly reduced with the couplingcompromised CXCR4-N119K-vYFP mutant (Fig. 4C) , indicating that the engagement of G␣ i1 by the heterooligomer on CCR2 activation involves a functional CXCR4 and thus includes the unliganded protomers.
G-protein activation and calcium mobilization
To further explore potential functional cooperativity within the CXCR4/CCR2 heterooligomer, we assessed the effect of SDF-1 and MCP-1 costimulation on G-protein activation. As shown in Fig. 5A , activation of cells coexpressing CXCR4 and CCR2 with either SDF-1 or MCP-1 led to equivalent G␣ i1 activation, as monitored with a BRET-based G-protein activation biosensor (44) detecting the receptor-promoted separation between G␣ i1 -RlucII and GFP10-G␥ 1 . Activation with rotigotine in cells expressing the D2R alone resulted in similar extent of G␣ i1 activation. Costimulation with equimolar concentrations of SDF-1 and MCP-1 did not lead to further activation, suggesting a lack of detectable cooperativity in this assay configuration. However, as illustrated in Fig. 6A , B, both CXCR4 and CCR2 expressed individually and on stimulation with their respective agonists SDF-1 and MCP-1 led to a significant calcium mobilization. On coexpression of the 2 receptors, each ligand maintained a similar ability to promote the calcium response. However, costimulation of the 2 receptors with equimolar concentrations of SDF-1 and MCP-1 resulted in a change of the calcium response that was characterized by a faster and more transient response that yielded a higher maximal concentration of cytoplasmic calcium (Fig. 6C) . In fact, the height of the calcium response induced by the combined agonists was higher than that expected from the simple addition of the responses observed with the individual ligands, indicative of a synergy between the 2 responses that may reflect heterooligomer activity.
In addition, whereas PTX treatment completely blocked the CXCR4-promoted calcium response, Ͼ50% of the CCR2 response was resistant to the toxin treatment, indicating the contribution of a distinct G protein to the CCR2 response (Fig. 6D, E) . Costimula- tion of the 2 receptors with equimolar concentrations of SDF-1 and MCP-1 resulted in a response that was also blocked by 50% on PTX treatment (Fig. 6F) , strongly suggesting that the heterooligomer-promoted calcium response is partially resistant to PTX. Because G␣ z is the only member of the G␣ i family that is resistant to PTX, we tested the ability of SDF-1 and MCP-1 to activate G␣ z in cells expressing CXCR4, CCR2, or both receptors (Fig. 5B) . We found that CCR2 but not CXCR4 promotes a robust decrease in BRET between G␣ z -94Rluc and GFP10-G␥ 1 , suggesting that G␣ z is responsible for the PTX-resistant calcium mobilization. Equimolar coactivation of CCR2 and CXCR4 resulted in an activation of G␣ z that is similar to the activation of CCR2 alone, indicating that the heterodimer preserved the ability to activate G␣ z that underlie the PTX-resistant calcium response.
Engagement of ␤arrrestin by a CXCR4/CCR2 heterooligomer
To further characterize the ability of the homo-and heterooligomers to interact with other downstream effectors, we also assessed the recruitment of ␤arrestin2 to homo-and heterooligomers of CXCR4 and CCR2. As shown in Fig. 7A , B, SDF-1 and MCP-1 promoted a time-dependent increase in BRET between ␤arrestin2-RlucII and either CXCR4-V1/V2 or CCR2V1/V2 in cells expressing the individual homodimers. Interestingly, the recruitment kinetics were different for the 2 receptors; the rate of ␤arrestin engagement being faster for CCR2. As was the case for the engagement of G␣ i1 , activation of CCR2 with MCP-1 did promote recruitment of ␤arrestin2-RlucII to the CCR2/ CXCR4-V1/CXCR4-V2 complex (Fig. 7C) . No effect of MCP-1 was observed in cells coexpressing CXCR4-V1/V2 and ␤arrestin2-RlucII in the absence of CCR2. Similarly, no BRET was detected in cells coexpressing the CXCR4 and D2R on stimulation with quinpirole ( Fig. 7C) , an agonist known to promote ␤arrestin2 recruitment to the D2R (53) . Consistent with a recruitment of ␤arrestin2 to the heterooligomer, both MCP-1 and SDF-1 induced a concentration-dependent recruitment of ␤arrestin2-RlucII to the CXCR4-V1/CCR2-V2 heterodimer complex (Fig. 8C, D) . The EC 50 of SDF-1 for the CXCR4 homodimers (Fig. 8A ) and the CXCR4/CCR2 heterodimer (Fig. 8C) configurations were 12.6 and 4.8 nM, respectively, consistent with the affinity of SDF-1 for the CXCR4 receptor. However, the EC 50 of MCP-1 for the ␤arrestin2 recruitment to the CXCR4/CCR2 heterodimer configuration was 32.3 nM, a potency significantly lower than its affinity for CCR2, indicating that the MCP-1-bound CXCR4/CCR2 hererodimer has a relatively low affinity for ␤arrestin2. Interestingly, similarly to what was observed for the recruitment of ␤arrestin2-RlucII to the CXCR4-V1/CXCR4-V2 homodimer (Fig. 8A, B) , TC14012 completely blocked the SDF-1-promoted recruitment of ␤arrestin2-RlucII to the CXCR4-V1/CCR2-V2 complex (Fig. 8C) . However, the CXCR4 inverse agonist was without effect on the maximal ability or the EC 50 of MCP-1 to promote the engagement of ␤arrestin2-RlucII to CXCR4-V1/ CCR2-V2 (Fig. 8D) , consistent with the lack of effect of TC14012 on the MCP-1 promoted conformational change of the CXCR4 dimer observed in Fig. 1C . To assess the possible cooperativity between CXCR4 and CCR2 on the ␤arrestin2 recruitment, equimolar concentrations of SDF-1 and MCP-1 were added simultaneously. As shown in Fig. 8E , the combination of the 2 agonists resulted in a concentration-dependent response equivalent to that of the MCP-1 alone, which was 3.5-fold greater than the response promoted by SDF-1 alone and could not be blocked by TC14012. This indicates that the greater response promoted by MCP-1 dominated for the heterodimer configuration when the 2 ligands were added. As for the larger BRET response promoted by MCP-1 compared to SDF-1, it could result either from a greater recruitment of ␤arrestin to the heterodimer through CCR2 than through CXCR4 activation or from different conformations of the CXCR4/ CCR2/␤arrestin complex promoted by the 2 ligands that would result in different distances between the reconstituted vYFP and the Rluc. Taken together, these data indicate that, as is the case for G␣ i1 , ␤arrestin2 can be engaged by a CCR2-CXCR4 heterooligomer in response to the activation of a single receptor subtype.
Despite this lack of effect of TC14012 on the MCP-1-promoted ␤arrestin recruitment to the CXCR4-CCR2 heterooligomer, the G-protein-uncoupling mutation of CXCR4 affected the ability of both CXCR4 and of the CXCR4/CCR2 heterooligomer to recruit ␤arrestin2. As was found for the engagement of G␣ i1 , the N119K mutation completely inhibited the SDF-1 promoted recruitment of ␤arrestin2 to CXCR4 (Fig. 9A) . However, in contrast to the loss of CCR2-promoted engagement of G␣ i1 in cells coexpressing CCR2 and CXCR4-N119K, MCP-1 stimulation of CCR2 promoted a timedependent increase in the BRET signal between ␤arrestin2-RlucII and CXCR4-N119K-vYFP (Fig. 9B) . The maximal CCR2-promoted BRET signal was even higher than that observed between ␤arrestin2-RlucII and WT-CXCR4-vYFP, suggesting the occurrence of allosteric regulations within the heterooligomer that differentially affects the engagement of G␣ i1 and ␤arrestin.
DISCUSSION
In the present article, we have demonstrated that homo-and heterooligomeric assemblies of CXCR4 and CCR2 receptors can engage both G proteins and ␤arrestin on agonist stimulation, indicating that they represent functional forms of the receptors. The combination of BRET and PCA assays allowed determination that the CXCR4 homooligomer can include Ն4 molecules of CXCR4, whereas Ն2 CXCR4 and Ն2 CCR2 molecules can form a CXCR4/CCR2 heterooligomer. These observed arrangements suggest that the quaternary structure of oligomers may result from the assembly of homodimers. Yet, the heterooligomer behaves as an integral functional unit, since the ability of one of the subtypes to engage the effectors affects the ability of the complex as a whole to engage both the G protein and ␤arrestin.
When taken together, our results provide several lines of evidence indicating that CXCR4-CCR2 heterooligomers exist as integral functional units. First, selective binding of MCP-1 to CCR2 promotes a conformational rearrangement within a CXCR4 dimer, consistent with the occurrence of a transreceptor conformational rearrangement in a heterooligomer. Second, CCR2 activation leads to the engagement of G␣ i1 and ␤arrestin by a receptor complex including a dimer of CXCR4. Interestingly, whereas CXCR4 homooligomer was found to engage G␣ 13 , we could not detect any engagement of this G protein by the CCR2/CXCR4 heterooligomer. This contrasts with the detected engagement of G␣ i1 by the heterooligomer and may suggest a distinct signaling selectivity of the heterooligomer. Our study also reveals that, in addition to activating G␣ i1, CCR2 stimulation leads to the activation of the PTX-resistant G i family member G␣ z and PTXresistant calcium mobilization. No such activation was observed for CXCR4, unraveling different coupling F) were preincubated or not with 100 ng/ml PTX (D-F) overnight. Cells were then injected or not (vehicle) with either SDF-1 (100 nM), MCP-1 (100 nM), or MCP-1 ϩ SDF-1 (100 nM each), and luminescence was measured every 500 ms for 40 s after injection. Data were normalized to agonist-stimulated maximal calcium response (A-C). Orange line (C) represents the calculated additive effect of the response obtained after stimulation of SDF-1 and MCP-1 individually, to allow the visualization of the potentiation. Data are representative of 3 independent experiments (A-C) or are means Ϯ sem of the peak response (D, E) or means Ϯ sd (F) of 2-3 independent experiments. *P Ͻ 0.05, ***P Ͻ 0.001, ****P Ͻ 0.0001; unpaired 2-tailed Student's t test. selectivity for the 2 receptor subtypes. These findings support the notion that transdimer allosteric regulation can have signaling repercussions and may provide a structural basis underlying the cooperativity observed between CXCR4 and CCR2 in heterologous expression system as well as in leukocytes endogenously expressing the 2 receptor subtypes (19) . Consistent with this idea, costimulation of CXCR4 and CCR2 with SDF-1 and MCP-1 resulted in a calcium mobilization that is greater than that predicted by the simple addition of the calcium responses initiated by the stimulation with a single agonist in cells coexpressing the 2 receptors. However, the mechanism underlying such allosteric regulation remains to be elucidated since no evidence for positive or negative cooperativity could be detected at the level of G-protein or ␤arrestin engagement on coactivation of the 2 receptors by their cognate agonists or on concomitant blockade of CXCR4 with TC14012 and MCP-1 activation of CCR2.
Although oligomers of higher order than dimers have been suggested for other GPCRs, including the D2-dopamine (16), metabotropic GABA (11), M2-muscarinic (37), ␤2-adrenergic (13), serotonin 1A (5-HT 1A ) (18) , and rhodospsin (6), our PCA-BRET data provide direct evidence documenting conformational changes occurring within a tetramer on ligand binding. The ligand-promoted change in BRET observed between the Rluc and vYFP, which were reconstituted by 2 pairs of homodimers, could result either from an induction of the tetramer formation or conformational rearrangement of an existing tetramer induced directly by the binding of the ligand or as a consequence of the ligand-promoted recruitment of downstream signaling partners to the tetramer. Although the PCA configura- tions used in the present study have been shown to be reversible (16, 42) , one cannot exclude that the reconstitution of Rluc or vYFP may stabilize the homodimers and thus could increase their propensity to form larger oligomers. However, the fact that the PCA pairs that were used involved only previously validated homodimers rules out the possibility that the observed oligomers resulted from spuriously formed homodimers. The observation that CCR2 stimulation promotes an increase in BRET between 2 CXCR4 protomers in BRET experiments also confirm that the formation of heterooligomers is not dependent on PCA stabilization.
Although it has been suggested that allosteric regulatory processes could result from receptor heterodimerization, our study raises the possibility that these allosteric effects may involve higher order oligomers. Our data indicate that at least tetramers, formed either from 4 identical protomers or from 2 molecules of each subtype, can assemble, be responsive to ligands, and engage both G proteins and ␤arrestin. However, the exact signaling configurations of these complexes remain to be firmly established. For instance, whether the G protein is recruited under the CXCR4, the CCR2, or both protomers within the heterooligomer on CCR2 activation cannot be addressed directly by our study. However, the finding that a G-protein-uncoupling mutation of CXCR4 (CXCR4-N119K) abolishes the MCP-1-promoted BRET increase between G␣ i1 and CXCR4 underlines the importance of the unbound CXCR4 protomer on CCR2 stimulation. Yet, the exact stoichiometry between the receptors and the G proteins remains uncertain. For the LTB1 leukotriene receptor, it has been proposed that a single heterotrimeric G protein assembles with a receptor dimer (1) . A similar stoichiometry of 1 G protein/dimer has also been proposed for the class C GPCR mGluR1 (54) . If this is the case for the chemokine receptors, one could imagine that 2 G proteins could be recruited under the receptor heterotetramer. However, recent analysis with the class C GABA B R suggest that only one G protein can be activated by a receptor heterotetramer (17) . Additional studies will be required to establish the precise stoichiometry of the signaling complex.
Our data also clearly indicate that both CXCR4 homo-and CXCR4-CCR2 heterooligomers can recruit ␤arrestin2. Previous studies had provided indirect evidence that ␤arrestins could be recruited to receptor homo-or heterodimers (55, 56) . However, this is the first direct demonstration of the formation of a complex between ␤arrestin and either GPCR dimers or higher-order oligomers. A stoichiometry of 1 ␤arrestin to 1 receptor has previously been suggested for rhodopsin (57) . In that respect, note that, although the N119K mutation completely inhibited the BRET between CXCR4 and ␤arrestin on direct CXCR4 stimulation with SDF-1, the coexpression and stimulation of CCR2 with MCP-1 promoted a BRET signal between CXCR4-N119K-vYFP and ␤arrestin2-RlucII that was even higher than that observed between the WT-CXCR4-vYFP and ␤arrestin2-RlucII. This clearly indicates that a G␣ i1 coupling-competent CXCR4 protomer is not essential for the recruitment of ␤arrestin to the heterooligomer and that the allosteric effects of the N119K mutation within the heterooligomer have distinct implications for the engagement of ␤arrestin vs. G␣ i1 . Whether the BRET between the G i -coupling-compromised CXCR4-N119K mutant and ␤arrestin on CCR2 stimulation results from a recruitment to the transactivated CXCR4 that can still adopt a conformation amenable for ␤arrestin recruitment or from a recruitment to CCR2 bringing ␤arrestin into proximity with CXCR4-N119K, or both, cannot be established. However, the fact that the BRET kinetic increase is intermediary between the faster and slower kinetics observed for the direct recruitment to CCR2 and WT-CXCR4, respectively, indicates that the conformation adopted by the heterooligomer on activation is determinant for the recruitment of ␤arrestin. The higher maximal BRET observed with CXCR4-N119K vs. WT receptor is also consistent with this notion and may indicate that the lack of coupling of CXCR4-N119K to G␣ i1 may either directly or allosterically favor the recruitment of ␤arrestin to or in proximity to CXCR4 within the heterooligomer. Our observation, using BRET-PCA combinations, that G␣ i1 can be engaged by CXCR4 oligomers is congruent with recent findings demonstrating that both D1R and D2R homo-and heterodimers can engage their cognate G proteins (58) and suggests that assemblies between receptor oligomers and G protein may be generalized among GPCRs. These findings raise the question of selectivity of interaction. For instance, it could be hypothesized that the interactions with the same G-protein subtype may be sufficient to bring different receptors into proximity. This is most likely not the case, since the G␣ i -coupled D2R, used as a negative control throughout this study, was unable to form oligomers with CXCR4, modulate the conformation of a CXCR4 dimer, or affect the engagement of G␣ i or ␤arrestin by the CXCR4 oligomers. These data therefore suggest that the selectivity of heterooligomerization is conferred by receptor intrinsic characteristics and is not driven solely by their interaction with a common G-protein subtype.
GPCR transregulation within homodimers, whereby binding of a ligand to one protomer induces conformational changes to both monomers, has been previously proposed for the BLT1R (59) and D2R (60) . Similarly, transreceptor conformational changes were reported for the -opioid receptor (MOR)/␣2-adrenergic receptor heterodimer on activation of MOR (61) . In class C GPCRs, transprotomer conformational rearrangements have been observed for GABAbR1/R2 heterodimers (62) , and negative functional cooperativity has also been observed for GABAbR1/R2 in heterotetramers (17) . However, our study is the first to document transregulation of class A GPCR within a tetramer.
Our study raises the question of the quaternary arrangement of the GPCR heterooligomers. Heterodimers are generally seen as the assembly of 2 distinct GPCR monomers. However, our data open the possibility that heterooligomers may represent the assembly of 2 homodimers. Given that several studies indicate the requirement of dimers for ER exit and their possible involvement in hydrophobic mismatch ER quality control, the data suggest that the homodimers may represent the simplest building block of GPCR and that heterooligomers result from the assembly of distinct homodimers. This has obvious implications for the structural arrangements of the oligomers. The formation of heterooligomers from homodimers would imply that distinct interfaces are used for homodimerization and heterooligomerization. For the D2R, distinct symmetrical interfaces involving TMV-TMV and TMI-TMI contacts have been proposed as the basis for a higher-order oligomer (16) . The recent resolution of the 3D structure of CXCR4 revealed only one homodimerization interface involving transmembrane domains V and VI (36) , preventing any speculation on the organization of higher-order oligomers. For the MOR, in contrast, the solved structure presents 2 dimer interfaces: a small one involving a TMI-TMIIhelix 8 interaction and a larger one between TMV and TMVI (63) . The presence of these distinct interfaces on opposite sides of the receptor offers a plausible structural basis for the formation of higher-order oligomers. Further work will be needed to determine the interface involved in CXCR4 and CCR2 homo-and heterooligomerization.
In summary, our study clearly demonstrates that CXCR4 and CCR2 can form both homo-and heterooligomers composed of Ն4 protomers. Such tetramers composed of either 4 molecules of CXCR4 or 2 molecules of CCR2 and 2 molecules of CXCR4 are present at the plasma membrane, where their cognate ligands can promote conformational rearrangement of the oligomeric complex. Both G proteins and ␤arrestin can be engaged by the CXCR4-CCR2 heterooligomeric complex in response to the activation of one of the 2 receptor subtypes, confirming the functionality of the complex. Such quaternary arrangement offers a novel structural basis to explain the cooperative allosteric regulation observed for CXCR4 and CCR2 in monocytes and memory T cells, where they are naturally coexpressed.
